Raytelligence receives MDR labeling from the Medical Products Agency

EaZense has been registered with the Medical Products Agency and certified under MDR. This means that the product is approved in accordance with the EU regulation on medical devices that ensures the safety and performance of medical devices.

EaZense has been CE marked according to previously applicable directives for medical devices, MDD. The EU's new Medical Devices Regulation (MDR) replaced the MDD in May 2021.

Like all medical technology companies with products on the European market, Raytelligence has had to adapt its operations to meet the new requirements for CE marking of the products.

"Our sensorsystem EaZense has been registered with the Medical Products Agency and certified under MDR. The MDR certification is important because it certifies that the product continues to meet the EU's essential health, safety and environmental requirements. The application was submitted on 26 May" says Klas Arvidson, CEO Raytelligence

About the EU regulationThe regulation updates the rules on which medical devices may be on the market, and how products are provided and used. The regulation improves patient safety by introducing stricter methods for assessment and monitoring in the market. It also contains rules for how medical technology companies conduct product evaluations within the EU. This ensures that unsafe and incompatible products and equipment do not end up on the market.

Questions are referred to:

Klas Arvidson, CEO Raytelligence


+46 70 416 98 00

Raytelligence AB (publ)

Klammerdammsgatan 6

302 42 Halmstad


About Raytelligence AB (publ)

Raytelligence is a Swedish innovation company, based in Halmstad that offers products for monitoring vital parameters, ie breathing, heart rate and movement patterns, based on the company's own 60 GHz radar technology.

Nerladdningsbara filer

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
SE-102 45 Stockholm, Sweden

08-692 21 90

Om beQuoted